Pain After Covid-Multidisciplinary Action Network

由于COIVD-19感染，全球超过2亿患者(Pt)出现疲劳、广泛性肌肉疼痛、关节和胸痛。COVID后慢性疼痛的发病、病理生理学和临床病史知之甚少，这使得医生在具体识别和诊断PT以及开出最有效的治疗处方时无所适从。为了促进对COVID后慢性疼痛的认识，讨论目前的临床差距，为这些紧迫的问题开发潜在的解决方案，我们提议成立一个多学科联盟：-临床医生与长COVID患者合作，并对COVID后慢性疼痛综合征的特定知识进行研究。-特定环境下的慢性疼痛综合征的临床专家：儿科和慢性术后疼痛、慢性疼痛神经调节；-应用基因组学更好地了解疼痛病理生理学，并使用血糖学预测长期COVID，并对患者发展与严重疾病相关的长COVID的风险进行分层；-翻译科学家、药理学和纳米医学专家，开发新的纳米疗法来治疗慢性疼痛、炎症和免疫激活；-初创公司、对开发新的疼痛治疗工具感兴趣的老牌生物技术公司，包括参与药品/保健产品工业化的国际CDMO，传播理性方法治疗慢性术后疼痛和炎症性慢性疼痛的文化的科学协会(重定向)。

Over 200 million patients (pts) worldwide have fatigue, widespread muscle pain, joint andchest pain due to COIVD-19 infection. Little is known on onset, pathophysiology and clinicalhistory of chronic pain post-COVID, leaving doctors at loss when it comes to specificallyidentify and diagnose pts and prescribe most effective treatments. To advance knowledgeon post-COVID chronic pain, to discuss current clinical gaps, develop potential solutions forthese pressing issues we propose a multidisciplinary consortium:-clinicians working with long COVID pts and specific knowledge of chronic post-COVID painsyndrome.-clinical experts in chronic pain syndromes in specific settings: paediatric and chronicpostoperative pain, chronic pain neuromodulation;-basic scientists applying genomics for a better understanding of pain pathophysiology andusing glycomics to predict long COVID and stratify the risk of pts to develop long COVID associatedsevere illness;-translational scientists, pharmacology and nanomedicine experts for development of newnanotherapies to tackle chronic pain, inflammation and immune activation;-startups, established biotech companies interested in development of new therapeutic toolsfor pain, incl.an international CDMO involved in industrialization ofpharmaceutical/nutraceutical products, scientific associations (Redirect) for spreading theculture of rational approach to chronic postoperative pain and inflammatory chronic pain.